TLR7 agonist 2 NEW
| Price | $159 | $253 | $522 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: TLR7 agonist 2 | CAS No.: 1642857-69-9 |
| Purity: 98.98% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | TLR7 agonist 2 |
| Description | TLR7 agonist 2 (TLR7-IN-1) is a specific and effective Toll-like Receptor 7 (TLR7) agonist (LEC=0.4 μM). |
| Cell Research | The ability of TLR7-agonist-1 to activate human TLR7 and/or TLR8 is assessed by using HEK293 cells. Briefly, HEK293 cells are grown in culture medium (DMEM supplemented with 10% FCS and 2 mM Glutamine). Transfected cells are then detached with Trypsin-EDTA, washed in PBS and resuspended in medium to a density of 1.67×105 cells/mL. Thirty microliters of cells are then dispensed into each well in 384-well plates, where 10 μL of TLR7-agonist-1 in 4% DMSO is already present. Following 6 hours incubation at 37°C, 5% CO2, the luciferase activity is determined by adding 15 μL of Steady Lite Plus substrate to each well and readout performed on a microplate imager. Lowest effective concentrations (LEC) values are determined for TLR7-agonist-1. |
| Animal Research | In C57Bl/6 mice model,Single oral administration of 0.3, 1, 3, and 10 mg/kg doses of TLR7-agonist-1. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (133.79 mM) |
| Keywords | inhibit | TLR-7 agonist 2 | TLR7 agonist 2 | Inhibitor | Toll-like Receptor (TLR) |
| Inhibitors Related | Polyinosinic-polycytidylic acid sodium | CU-CPD107 | Imiquimod hydrochloride | Hydroxychloroquine | Chloroquine phosphate | Hydroxychloroquine sulfate | Chloranil | Chloroquine | CU-115 | Imiquimod | TLR3-IN-1 | Resiquimod |
| Related Compound Libraries | Nonsteroidal Anti-Inflammatory Compound Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | HIF-1 Signaling Pathway Compound Library | Pyroptosis Compound Library | NO PAINS Compound Library | Immuno-Oncology Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2150.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $0.00/5mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $50.00/1kg |
VIP5Y
|
Hebei Yanxi Chemical Co., Ltd.
|
2023-02-07 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY